On the surface of the surviving

erythrocytes, C3b is cleaved, leaving high numbers of C3d molecules on the cell surface. Complement activation may proceed beyond the C3b formation step, resulting in C5 activation, formation of the membrane attack complex and intravascular hemolysis. Due to surface-bound regulatory proteins such as CD55 and Sirolimus solubility dmso CD59, however, the complement activation is usually not sufficient to produce clinically significant activation of the terminal complement pathway. The major mechanism of hemolysis in stable disease, therefore, is the extravascular destruction of C3b-coated erythrocytes by the RES.[29], [30], [32] and [33] These mechanisms explain why the direct antiglobulin test (DAT) is strongly positive for C3d in patients with CA mediated hemolysis and, in a majority, negative for IgM and IgG. In up to 20% of patients with primary CAD, however, DAT is also weakly positive for IgG, which should not lead to a wrong diagnosis

of mixed-type AIHA.[6] and [34] Primary CAD accounts for about 15% of all cases Cobimetinib mw of AIHA.[1], [2] and [35] The prevalence in Norway has been estimated to 16 per million inhabitants and the incidence rate to 1 per million inhabitants per year.6 The median age of patients with CAD is 76 years (range, 51–96) with a median age at onset of symptoms of 67 years (range, 30–92).6 By definition, all patients with CAD have hemolysis, but occasional patients are not anemic because the hemolysis is fully compensated. Most patients, however, have manifest hemolytic anemia. Of 16 patients described in an early publication, five had hemoglobin (Hgb) levels below 7.0 g/dL and one had levels below 5.0 g/dL.36 Hgb levels ranged from 4.5 g/dL to normal in a more ROS1 recent population-based descriptive study of 86 Norwegian patients.6 In the same study, the median Hgb level was 8.9 g/dL and the lower tertile was 8.0 g/dL. Fifty per cent of the patients had been considered transfusion dependent for shorter or longer periods

during the course of the disease, and 70% had received drug therapy. Although the term ‘cold’ refers to the biological properties of the CA, not the clinical features, approximately 90% of the patients experienced cold-induced acrocyanosis and/or Raynaud phenomena.6 These symptoms ranged from slight to disabling. Characteristic seasonal variations in the severity of hemolytic anemia have been well documented.37 In at least two-thirds of the patients, exacerbation of hemolytic anemia is also triggered by febrile infections or major trauma.[6], [38] and [39] The explanation for this paradoxical exacerbation is that during steady-state CAD, most patients are complement-depleted with low levels of C3 and, in particular, C4. During acute phase reactions, C3 and C4 are repleted and complement-induced hemolysis increases.